

# HUMAN ANTIBODIES & HYBRIDOMAS

22-24 October 2018, Pullman Riga Old Town Hotel, Riga, Latvia



# FINAL ORAL & POSTER PROGRAMME HAH 2018

## SCIENTIFIC ADVISORY PANEL

Programme Chairman: Professor Mark Glassy (*UCSD Moores Cancer Center, San Diego, California, USA*)

Mirek Gorny (*New York University School of Medicine, New York, USA*)

Henry Lowman (*CytomX Therapeutics Inc., South San Francisco, California, USA*)

Chris Scott (*The Queen's University, Belfast, Northern Ireland, UK*)

Roberto Burioni (*Universita Vita-Salute San Raffaele, Milan, Italy*)

Jim Larrick (*Panorama Research Inc., USA*)

Alois Lang (*GeNeuro SA, Geneva, Switzerland*)

David P. Humphreys (*UCB, Slough, UK*)

Markus Enzelberger (*MorphoSys AG, Martinsried, Germany*)

Eszter Nagy (*Arsanis GmbH, Vienna, Austria*)

Sachdev Sidhu (*University of Toronto, Canada*)

Neil Brewis (*F-star, Cambridge, UK*)

Paul Kerr (*Fusion Antibodies, Northern Ireland, UK*)

Yan Wu (*Kadmon Pharmaceuticals LLC, New York, USA*)

Bob Kelley (*Genentech Inc., South San Francisco, USA*)

David Naor (*The Hebrew University, Jerusalem, Israel*)

Lynn MacDonald (*Regeneron Pharmaceuticals, Tarrytown, New York, USA*)

Jody Berry (*Becton Dickinson, La Jolla, California, USA*)

Maria Groves (*Medimmune, Cambridge, UK*)

Dale Ludwig (*ImClone Inc., New York, USA*)

Hermann Katinger and Dietmar Katinger

(*Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria*)

Andrew T. Serafini (*Kilpatrick Townsend, Seattle, Washington, USA*)



09.00-10.20

Registration

10.20-10.30

**Welcome & Opening Remarks**

HAH 2018 Conference Chairman Mark Glassy  
(UCSD, San Diego, California, USA)

**SESSION 1:  
OPENING PLENARY SESSION**

Moderator: Mark Glassy

(UCSD, San Diego, California, USA)

10.30-11.15

**KEYNOTE:**

**'Pentapeptide, targeting amyloid proteins, attenuates chronic inflammation, autoimmunity and neurodegeneration'**

David Naor

(The Lautenberg Center for General and Tumor Immunology, The Hebrew University – Hadassah Medical School, Jerusalem, Israel)

11.15-11.45

**KEYNOTE:**

**'New ways to use human antibodies:**

**From intracellular targets to switchable affinity'**

Stefan Dubel

(Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, Braunschweig, Germany)

11.45-12.15

**KEYNOTE:**

**'Pre-clinical development of mAbs for Crimean Congo Hemorrhagic Fever (CCHF)'**

Zachary Bornholdt

(Mapp Biopharmaceutical Inc., San Diego, California, USA)

12.15-12.45

**'Naturally occurring human immuno-modulatory IgM'**

Nelson N. Teng

(Stanford University School of Medicine, Stanford, California, USA)

12.45-14.00

Lunch Break

**SESSION 2:**

**ANTIBODY MANIPULATIONS: IMMUNE CHECKPOINT INHIBITION AND AFFINITY MATURATION**

Moderator: Lynn MacDonald

(Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA)

14.00-14.30

**'Identification of a PDL-1 binding fcab:**

**A potent inhibitor of immunosuppressive signals'**

Neil Brewis

(F-star Biotechnology Ltd., Babraham Research Campus, Cambridge, UK)

14.30-15.00

**'GNbAC1 a non-immunomodulatory mAb for multiple sclerosis: Promises and challenges'**

Francois Curtin and Alois Lang

(GeNeuro SA, Geneva, Switzerland)

15.00-15.30

**'Rational library design for antibody affinity maturation'**

Richard Buick

(Fusion Antibodies Ltd., Belfast, Northern Ireland, UK)

15.30-16.00

Tea Break

**SESSION 3:**

**NOVEL METHODOLOGIES IN ANTIBODY PRODUCTION**

Moderator: Jim Larrick

(Panorama Research, Sunnyvale, California, USA)

16.00-16.30

**'Antibody- and complement-humanized mice'**

Lynn MacDonald

(Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA)

16.30-16.50

**'Molecular determinants for primumab activity'**

Mark Glassy

(UCSD, San Diego, California, USA)

16.50-17.20

**'Next generation technology for membrane proteins and antibody development'**

Mart Ustav

(Terrence Donnelly Centre for Biomolecular Research, University of Toronto, Toronto, Ontario, Canada)

17.20-18.00

**SPECIAL KEYNOTE:**

**'Protecting Innovation: Therapeutic Antibodies'**

Andrew T. Serafini

(Kilpatrick Townsend & Stockton LLP, Seattle, Washington, USA)



## SESSION 4: METHODS AND TECHNOLOGIES IN THE ANTIBODY DISCIPLINE

Moderator: Alois Lang

*(GeNeuro SA, Geneva, Switzerland)*

09.00-09.30

**'Antigen-specific plasma cell identification using droplet microfluidics'**

Pierre Bruhns

*(Institut Pasteur, Paris, France)*

09.30-10.00

**'Medical Counter Measure (MCM) Development at Mapp: Using mAbs to treat Filovirus diseases'**

Larry Zeitlin

*(Mapp Biopharmaceutical Inc., San Diego, California, USA)*

10.00-10.30

**'Antibody hit discovery using yeast surface display'**

Lars Toleikis and Stefan Zielonka

*(Merck Biopharma, Merck KGaA Darmstadt, Germany)*

10.30-11.00

Coffee Break

## SESSION 5: THERAPEUTIC TARGETS AND ANTIBODY IMMUNOTHERAPY

Moderator: Pierre Bruhns

*(Institut Pasteur, Paris, France)*

11.00-11.30

**'MoGRAA® discovery engine can expand the drug targets of therapeutic mAb'**

Kiyoshi Takayama

*(NB Health Laboratory Co., Ltd., Kita-ku, Sapporo City, Hokkaido, Japan)*

11.30-12.00

**'Cell-only pipelines and droplet microfluidics for the rapid discovery of novel antibody therapeutics'**

Niccolo Pengo

*(Antibody Discovery, UCB-Celltech, Slough, Berkshire, UK)*

12.00-12.30

**'On target hexamerisation of IgG1 driven by a mutant form of IgM tail-piece C-terminal fusion'**

David Humphreys

*(UCB, Slough, Berkshire, UK)*

12.30-14.00

Lunch Break

## SESSION 6: PRECLINICAL VALIDATION AND THERAPEUTIC ANTIBODY DISCOVERY

Moderator: Paul Kerr

*(Fusion Antibodies Ltd., Belfast, Northern Ireland, UK)*

14.00-14.30

**'Therapeutic human antibody discovery and optimisation by mammalian display'**

Peter Slavny

*(IONTAS Ltd., Pampisford, Cambridge, UK)*

14.30-15.00

**'Using Hybrifree-discovered and CDRx humanized antibodies for drug discovery of challenging targets and for therapeutic development'**

Meelis Kadaja

*(Icosagen Cell Factory OU, Tartumaa, Estonia)*

15.00-15.30

**'Anthracycline-based ADCs with potent immune-stimulatory functions: Preclinical validation in solid and hematological tumor models'**

Lukas Bammert

*(NBE-Therapeutics Ltd., Basel, Switzerland)*

15.30-16.00

Tea Break

## SESSION 7: NOVEL APPROACHES IN ANTIBODY DESIGN

Moderator: David Naor

*(The Hebrew University – Hadassah Medical School, Jerusalem, Israel)*

16.00-16.30

**'High specificity mAbs against antibiotic resistant bacteria'**

Joël Henneghien and Didier Argentin

*(SynAbs, Chareloi, Belgium)*

16.30-17.00

**'Does the degree of antibody maturation influence expression rate and stability of mAbs?'**

Renate Kunert, Linda Schwaigerlehner and Patrick Mayrhofer

*(Department of Biotechnology, VIBT, University of Natural Resources and Life Sciences, Vienna, Austria)*

17.00-17.30

**'Re-bridging of antibody disulphide bonds: Applications in nanoparticle functionalisation'**

Michelle Green

*(Queen's University Belfast, Belfast, Northern Ireland, UK)*

17.30-18.00

**'In vivo antibody gene delivery: DNA-encoded monoclonal antibodies (dMAbs™)'**

Trevor Smith

*(Inovio Inc., San Diego, California, USA)*

**SESSION 8:  
ANTIBODIES, THEIR ANTIGENS AND IMMUNOTHERAPY**

Moderator: Jim Larrick

(Panorama Research, Sunnyvale, California, USA)

09.00-09.30

**'CD79: A promising target for immune-modulation'**

Jim Larrick

(Panorama Research, Sunnyvale, California, USA)

09.30-10.00

**'Disialo glycosphingolipid specific chimeric antigen receptors generated from antibody fragments of tumor-infiltrating B lymphocytes in triple negative invasive ductal carcinoma of the breast'**

Beatrix Kotlan<sup>1</sup>, Orsolya Csuka<sup>2</sup>, Szabolcs Horvath<sup>3</sup>, Klara Eles<sup>3</sup>, Jozsef Toth<sup>3</sup>, Judit Olasz<sup>2</sup>, Emil Farkas<sup>4</sup>, Akos Savolt<sup>4</sup>, Andras Szollar<sup>4</sup>, Istvan Vamosi-Nagy<sup>4</sup>, Mihaly Ujhelyi<sup>4</sup>, Laszlo Toth<sup>4</sup>, Miklos Kasler<sup>5,6</sup> and Gabriella Liszka<sup>7</sup>

(<sup>1</sup> Department of Tumorimmunology and Toxicology, <sup>2</sup> Department of Pathogenetics, <sup>3</sup> Center of Surgical and Molecular Pathology, <sup>4</sup> Center of Oncosurgery, National Institute of Oncology, Budapest, <sup>5</sup> Board of Directorship, National Institute of Oncology, <sup>6</sup> Ministry of Human Capacities, Budapest, <sup>7</sup> Department of Oncodermatology, National Institute of Oncology, Budapest, Hungary)

10.00-10.30

**'Combination of mouse Mab from syngeneic and ovine and goat Mab's from xenogeneic hybridomas for detection of some important antigen'**

V. Sologub, I. Koromyslova, L. Dudnikov and A. Biryukov

(Research Centre of Molecular Diagnostics, Moscow, Russia)

10.30-11.00

**'Characterization of monoclonal antibodies against human myeloperoxidase'**

N.P. Gorbunov<sup>1,2</sup>, A.V. Sokolov<sup>1,3,4</sup>, V.A. Kostevich<sup>1,3</sup> and O.M. Panasenko<sup>3</sup>

(<sup>1</sup> Institute of Experimental Medicine, Saint Petersburg, Russia; <sup>2</sup> State Research Institute of Highly Pure Biopreparations, FMBA of Russia, Saint Petersburg, Russia; <sup>3</sup> Research Institute of Physico-Chemical Medicine, FMBA of Russia, Moscow, Russia; <sup>4</sup> Saint Petersburg State University, Saint Petersburg, Russia)

11.00-11.30

Coffee Break

11.30-12.00

**SESSION 9:  
LATEBREAKER SESSION**

Moderator: Mark Glassy

(UCSD, San Diego, California, USA)

12.30

Lunch & Departure

\* This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

